Literature DB >> 23250755

Phosphorylation of IκBα at serine 32 by T-lymphokine-activated killer cell-originated protein kinase is essential for chemoresistance against doxorubicin in cervical cancer cells.

Jung-Hwan Park1, Dae-Sung Yoon, Hye-Jin Choi, Dae-Hyun Hahm, Sang-Muk Oh.   

Abstract

T-lymphokine-activated killer cell-originated protein kinase (TOPK) is known to be up-regulated in cancer cells and appears to contribute to cancer cell proliferation and survival. However, the molecular mechanism by which TOPK regulates cancer cell survival still remains elusive. Here we show that TOPK directly interacted with and phosphorylated IκBα at Ser-32, leading to p65 nuclear translocation and NF-κB activation. We also revealed that doxorubicin promoted the interaction between nonphosphorylated or phosphorylated TOPK and IκBα and that TOPK-mediated IκBα phosphorylation was enhanced in response to doxorubicin. Also, exogenously overexpressed TOPK augmented transcriptional activity driven by either NF-κB or inhibitor of apoptosis protein 2 (cIAP2) promoters. On the other hand, NF-κB activity including IκBα phosphorylation and p65 nuclear translocation, as well as cIAP2 gene expression, was markedly diminished in TOPK knockdown HeLa cervical cancer cells. Moreover, doxorubicin-mediated apoptosis was noticeably increased in TOPK knockdown HeLa cells, compared with control cells, which resulted from caspase-dependent signaling pathways. These results demonstrate that TOPK is a molecular target of doxorubicin and mediates doxorubicin chemoresistance of HeLa cells, suggesting a novel mechanism for TOPK barrier of doxorubicin-mediated cervical cancer cell apoptosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23250755      PMCID: PMC3561577          DOI: 10.1074/jbc.M112.422170

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  T-LAK cell-originated protein kinase (TOPK) phosphorylation of Prx1 at Ser-32 prevents UVB-induced apoptosis in RPMI7951 melanoma cells through the regulation of Prx1 peroxidase activity.

Authors:  Tatyana A Zykova; Feng Zhu; Tatyana I Vakorina; Jishuai Zhang; Lee Ann Higgins; Darya V Urusova; Ann M Bode; Zigang Dong
Journal:  J Biol Chem       Date:  2010-07-20       Impact factor: 5.157

2.  PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.

Authors:  F Hu; R B Gartenhaus; D Eichberg; Z Liu; H-B Fang; A P Rapoport
Journal:  Oncogene       Date:  2010-07-12       Impact factor: 9.867

3.  Ras puts the brake on doxorubicin-mediated cell death in p53-expressing cells.

Authors:  Sunil K Manna; Charitha Gangadharan; Damodar Edupalli; Nune Raviprakash; Thota Navneetha; Sidharth Mahali; Maikho Thoh
Journal:  J Biol Chem       Date:  2010-12-14       Impact factor: 5.157

4.  Requirement of T-lymphokine-activated killer cell-originated protein kinase for TRAIL resistance of human HeLa cervical cancer cells.

Authors:  Hyeok-Ran Kwon; Ki Won Lee; Zigang Dong; Kyung Bok Lee; Sang-Muk Oh
Journal:  Biochem Biophys Res Commun       Date:  2009-11-27       Impact factor: 3.575

5.  Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin.

Authors:  Maria A Tapia; Irene González-Navarrete; Alba Dalmases; Marta Bosch; Vanesa Rodriguez-Fanjul; Mark Rolfe; Jeffrey S Ross; Jovita Mezquita; Cristobal Mezquita; Oriol Bachs; Pere Gascón; Federico Rojo; Rosario Perona; Ana Rovira; Joan Albanell
Journal:  Cell Cycle       Date:  2007-07-10       Impact factor: 4.534

6.  Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase.

Authors:  Akinori Yoda; Kyoko Toyoshima; Yasuhide Watanabe; Nobuyuki Onishi; Yuki Hazaka; Yusuke Tsukuda; Junichi Tsukada; Takeshi Kondo; Yoshiya Tanaka; Yasuhiro Minami
Journal:  J Biol Chem       Date:  2008-05-15       Impact factor: 5.157

7.  Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.

Authors:  Feng Zhu; Tatyana A Zykova; Bong Seok Kang; Zhe Wang; Mara C Ebeling; Yasuhito Abe; Wei-Ya Ma; Ann M Bode; Zigang Dong
Journal:  Gastroenterology       Date:  2007-04-25       Impact factor: 22.682

Review 8.  IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer.

Authors:  Mads Gyrd-Hansen; Pascal Meier
Journal:  Nat Rev Cancer       Date:  2010-08       Impact factor: 60.716

9.  Addressing reported pro-apoptotic functions of NF-kappaB: targeted inhibition of canonical NF-kappaB enhances the apoptotic effects of doxorubicin.

Authors:  Brian K Bednarski; Albert S Baldwin; Hong Jin Kim
Journal:  PLoS One       Date:  2009-09-10       Impact factor: 3.240

10.  Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms.

Authors:  Ana M Jiménez-Lara; Ana Aranda; Hinrich Gronemeyer
Journal:  Mol Cancer       Date:  2010-01-26       Impact factor: 27.401

View more
  8 in total

1.  Therapeutic effect of lymphokine-activated killer cells treated with low-dose ionizing radiation on osteosarcoma.

Authors:  Lei Zhao; Ming Lv; Wuliya Sayimu; Wei Liu; Huawu Zhang; B O Jiang; Dong Wang
Journal:  Oncol Lett       Date:  2015-05-27       Impact factor: 2.967

Review 2.  The role of T-LAK cell-originated protein kinase in targeted cancer therapy.

Authors:  Lu Zhang; Fei Wang; Huijun Yi; Svetlana P Ermakova; Olesya S Malyarenko; Jianmei Mo; Yingze Huang; Qiuhong Duan; Juanjuan Xiao; Feng Zhu
Journal:  Mol Cell Biochem       Date:  2022-01-17       Impact factor: 3.396

3.  Bee venom inhibits growth of human cervical tumors in mice.

Authors:  Hye Lim Lee; Sang Ho Park; Tae Myoung Kim; Yu Yeon Jung; Mi Hee Park; Sang Hyun Oh; Hye Seok Yun; Hyung Ok Jun; Hwan Soo Yoo; Sang-Bae Han; Ung Soo Lee; Joo Hee Yoon; Min Jong Song; Jin Tae Hong
Journal:  Oncotarget       Date:  2015-03-30

4.  TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.

Authors:  Ying Li; Zhiwei Yang; Weijie Li; Shudi Xu; Tao Wang; Ting Wang; Mengjie Niu; Shengli Zhang; Lintao Jia; Shengqing Li
Journal:  Oncotarget       Date:  2016-02-09

5.  T-lymphokine-activated killer cell-originated protein kinase (TOPK) as a prognostic factor and a potential therapeutic target in glioma.

Authors:  Chuntao Quan; Juanjuan Xiao; Qiuhong Duan; Ping Yuan; Peipei Xue; Hui Lu; Meng Yan; Dongsheng Guo; Sanpeng Xu; Xiaohui Zhang; Xuan Lin; Yong Wang; Soner Dogan; Jianmin Zhang; Feng Zhu; Changshu Ke; Lin Liu
Journal:  Oncotarget       Date:  2017-12-26

Review 6.  T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics.

Authors:  Katharine J Herbert; Thomas M Ashton; Remko Prevo; Giacomo Pirovano; Geoff S Higgins
Journal:  Cell Death Dis       Date:  2018-10-24       Impact factor: 8.469

7.  PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells.

Authors:  Jung-Hwan Park; Sang-Ah Park; Young-Ju Lee; Hwan-Woo Park; Sang-Muk Oh
Journal:  FEBS Open Bio       Date:  2020-04-14       Impact factor: 2.693

8.  Potent anti-myeloma activity of the TOPK inhibitor OTS514 in pre-clinical models.

Authors:  Andrew T Stefka; David Johnson; Shaun Rosebeck; Jae-Hyun Park; Yusuke Nakamura; Andrzej J Jakubowiak
Journal:  Cancer Med       Date:  2019-11-12       Impact factor: 4.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.